MetaCap

Gain Therapeutics (GANX) vs Werewolf Therapeutics (HOWL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Gain Therapeutics (GANX) over the past year, gaining 8.4% versus a loss of 62.4%. Over five years, GANX leads with a -87.3% price change compared with -93.7% for HOWL. Werewolf Therapeutics is the larger company by market cap ($46.0 million vs $44.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GANX-62.43%HOWL+8.43%
+63%-4%-71%
Nov 21, 20251 yearNov 20, 2026
GANX-87.92%HOWL-94.08%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GANX versus HOWL key metrics
MetricGANXHOWL
Share price$0.9994$0.9466
Market cap$44.50M$46.00M
1-day change-4.82%-3.97%
YTD return-68.96%+49.31%
1-year return-62.43%+8.43%
5-year return-87.27%-93.68%
EPS (TTM)$-0.42$-0.58
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-20.16M$-60.82M
52-week high$4.34$1.20
52-week low$0.94$0.27
Distance from 52-week high-76.97%-21.12%
Analyst consensusstrong_buynone
Avg. price target upside+620.43%+639.49%
Average volume550.22K1.08M
Shares outstanding44.53M48.60M
Employees2039
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HOWL has outperformed GANX by 70.9 percentage points over the past year.

About Gain Therapeutics

GANX stock →

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

GANX vs HOWL FAQ

Which is bigger, Gain Therapeutics or Werewolf Therapeutics?

Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $46.00M compared with $44.50M for Gain Therapeutics (GANX).

Which stock has performed better over the past year, GANX or HOWL?

HOWL returned +8.43% over the past 12 months, compared with -62.43% for GANX (price return, excluding dividends). Past performance does not predict future results.

Are Gain Therapeutics and Werewolf Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons